Valuation: Tonix Pharmaceuticals Holding Corp.

Market Cap 197M 172M 158M 147M 279M 18.73B 284M 1.9B 738M 9.21B 738M 723M 31.73B P/E 2026 *
-1.2x
P/E 2027 * -1.99x
Enterprise Value 197M 172M 158M 147M 279M 18.73B 284M 1.9B 738M 9.21B 738M 723M 31.73B EV / Sales 2026 *
5.75x
EV / Sales 2027 * 2.49x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tonix Pharmaceuticals Holding Corp.

1 day-0.80%
1 week-6.66%
Current month-3.29%
1 month+3.87%
3 months-11.22%
6 months-25.44%
Current year-21.00%
1 week 12.13
Extreme 12.13
13.41
1 month 10.03
Extreme 10.03
13.57
Current year 10.03
Extreme 10.03
19.95
1 year 10.03
Extreme 10.03
69.97
3 years 6.76
Extreme 6.76
6,016
5 years 6.76
Extreme 6.76
704,000
10 years 6.76
Extreme 6.76
1,000,000
Manager TitleAgeSince
Chief Executive Officer 68 2007-11-15
Director of Finance/CFO 52 2016-01-31
Chief Tech/Sci/R&D Officer - 2024-12-02
Director TitleAgeSince
Director/Board Member 78 2018-02-12
Director/Board Member 66 2020-06-08
Director/Board Member 81 2018-09-04
Date Insider Type Main position Quantity % Market Cap.
06-11Buy

Director

1,415 0.0120%
06-08Buy

Chief Executive Officer

5,000 0.0425%
06-07Buy

Director

5,000 0.0425%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-6.66%-65.22%-99.76% 197M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+31.35%+24.29% 338B
-0.56%+0.96%+39.86%+36.64% 299B
-0.08%+1.30%+30.37%+44.02% 291B
-1.54%+2.81%-27.56%-39.45% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.81%+4.42%+21.37%+42.06% 369.26B
Weighted average by Cap. +2.24%+5.53%+41.77%+83.00%

Financials

2026 *2027 *
Net sales 34.18M 29.88M 27.46M 25.6M 48.56M 3.25B 49.29M 330M 128M 1.6B 128M 126M 5.51B 78.93M 69M 63.41M 59.11M 112M 7.52B 114M 761M 296M 3.69B 296M 290M 12.73B
Net income -170M -149M -137M -127M -241M -16.18B -245M -1.64B -637M -7.95B -638M -624M -27.41B -152M -133M -122M -114M -216M -14.46B -219M -1.46B -569M -7.11B -570M -558M -24.49B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
26-07-02 US$12.34 -0.80% 326,682
26-07-01 US$12.44 -2.51% 288,441
26-06-30 US$12.76 +0.08% 308,781
26-06-29 US$12.75 -3.56% 525,674
26-06-26 US$13.22 +10.35% 1,608,875
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.34USD
Average target price
42.20USD
Spread / Average Target
+241.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNXP Stock